Artemether

Contraindicated

Artemether Ketoconazole Topical Extina® Foam Increased artemether/lumefantrine exposure, an increased risk of QT interval prolongation, reduced ketoconazole exposure and reduc... Details

Major

Artemether Amitriptyline Elavil Explained An increased risk of QT interval prolongation Details Artemether Sertraline Explained An increased risk of QT interval prolongation, reduced CYP3A4 substrates exposure and reduced efficacy of CYP3A4 substrates Details Artemether Buprenorphine Belbuca Explained An increased risk of QT interval prolongation, reduced CYP3A4 substrates exposure and reduced efficacy of CYP3A4 substrates Details Artemether Amisulpride Injection Barhemsys An increased risk of QT interval prolongation Details Artemether Arsenic Trioxide Trisenox An increased risk of QT interval prolongation Details Artemether Aripiprazole Injection Abilify An increased risk of QT interval prolongation, reduced CYP3A4 substrates exposure and reduced efficacy of CYP3A4 substrates Details Artemether Arsenic Trioxide Injection Trisenox An increased risk of QT interval prolongation Details Artemether Asciminib Scemblix Increased artemether/lumefantrine exposure, an increased risk of QT prolongation, reduced CYP3A4 substrate exposure and reduced ef... Details Artemether Asenapine Transdermal Patch Secuado An increased risk of QT interval prolongation Details Artemether Azithromycin AzaSite Increased artemether/lumefantrine exposure and an increased risk of QT prolongation Details Artemether Belumosudil Rezurock Explained Increased artemether/lumefantrine exposure, an increased risk of QT prolongation, reduced CYP3A4 substrate exposure and reduced ef... Details Artemether Atorvastatin Atorvaliq Increased artemether/lumefantrine exposure, an increased risk of QT prolongation, reduced CYP3A4 substrate exposure and reduced ef... Details Artemether Alfuzosin UroXatral An increased risk of QT interval prolongation, reduced CYP3A4 substrates exposure and reduced efficacy of CYP3A4 substrates Details Artemether Amlodipine Amvaz® Increased artemether/lumefantrine exposure, an increased risk of QT prolongation, reduced CYP3A4 substrate exposure and reduced ef... Details Artemether Anagrelide Agrylin An increased risk of QT interval prolongation Details Artemether Bedaquiline Sirturo An increased risk of QT interval prolongation, reduced CYP3A4 substrates exposure and reduced efficacy of CYP3A4 substrates Details Artemether Brigatinib Alunbrig Reduced artemether/lumefantrine exposure, reduced efficacy of artemether/lumefantrine, loss of antimalarial efficacy, reduced CYP3... Details Artemether Chloroquine Aralen® An increased risk of QT interval prolongation Details Artemether Cyclosporine Injection Atopica Increased artemether/lumefantrine exposure, an increased risk of QT prolongation, reduced CYP3A4 substrate exposure and reduced ef... Details Artemether Cyclosporine Ophthalmic Cequa Increased artemether/lumefantrine exposure, an increased risk of QT prolongation, reduced CYP3A4 substrate exposure and reduced ef... Details Artemether Darolutamide Nubeqa Reduced artemether/lumefantrine exposure, reduced efficacy of artemether/lumefantrine, loss of antimalarial efficacy, reduced CYP3... Details Artemether Dasatinib Phyrago An increased risk of QT interval prolongation, reduced CYP3A4 substrates exposure and reduced efficacy of CYP3A4 substrates Details Artemether Degarelix Injection Firmagon An increased risk of QT interval prolongation Details Artemether Deutetrabenazine Austedo An increased risk of QT interval prolongation Details Artemether Dexamethasone Injection Decadron Reduced artemether/lumefantrine exposure, reduced efficacy of artemether/lumefantrine, loss of antimalarial efficacy, reduced CYP3... Details Artemether Dexamethasone Ophthalmic Dexacidin® (as a combination product containing Dexamethasone, Neomycin, Polymyxin B) Reduced artemether/lumefantrine exposure, reduced efficacy of artemether/lumefantrine, loss of antimalarial efficacy, reduced CYP3... Details Artemether Disopyramide Norpace An increased risk of QT interval prolongation Details Artemether Dofetilide Tikosyn An increased risk of QT interval prolongation, reduced dofetilide exposure and reduced efficacy of dofetilide Details Artemether Dolasetron Anzemet An increased risk of QT interval prolongation Details Artemether Dolasetron Injection Anzemet An increased risk of QT interval prolongation Details Artemether Encorafenib Braftovi Reduced artemether/lumefantrine exposure, reduced efficacy of artemether/lumefantrine, loss of antimalarial efficacy, reduced CYP3... Details Artemether Entrectinib Rozlytrek Increased artemether/lumefantrine exposure, an increased risk of QT prolongation, reduced CYP3A4 substrate exposure and reduced ef... Details Artemether Erdafitinib Balversa Increased artemether/lumefantrine exposure, an increased risk of QT prolongation, reduced CYP3A4 substrate exposure and reduced ef... Details Artemether Eribulin Injection Halaven An increased risk of QT interval prolongation Details Artemether Everolimus Afinitor Increased artemether/lumefantrine exposure, an increased risk of QT prolongation, reduced CYP3A4 substrate exposure and reduced ef... Details Artemether Famotidine Calmicid An increased risk of QT interval prolongation Details Artemether Famotidine Injection Calmicid An increased risk of QT interval prolongation Details Artemether Felbamate Felbatol An increased risk of QT interval prolongation Details Artemether Flecainide Tambocor® An increased risk of QT interval prolongation Details